EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Return to full baseline functionality after repeated intermittent use of midazolam nasal spray in patients with seizure clusters: Post hoc analysis of an open-label extension trial

Kamil Detyniecki, Marcus Brunnert, Rita Campos, Svetlana Dimova, James W Wheless

Epilepsy & Behavior · 2023-11 · 148 · 109483

DOI: 10.1016/j.yebeh.2023.109483 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsy & Behavior, 2023-11. Verfasst von Kamil Detyniecki und 4 weiteren Autor:innen. Beteiligte Einrichtung: University of Miami Comprehensive Epilepsy Center, University of Miami Miller School of Medicine, 1150 NW 14th Street #309, Miami, FL 33136, USA. Ele…. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UCB Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To characterize the time to return to full baseline functionality (RTFBF) in seizure cluster episodes (SCEs) treated with one or two midazolam nasal spray (MDZ-NS/Nayzilam®) doses over the course of repeated intermittent use in patients with seizure clusters (SCs). METHODS: Post hoc analysis of an open-label extension trial in patients (≥12 years) with SCs (ARTEMIS-2/P261-402: NCT01529034, 2011-004109-25). Caregivers administered MDZ-NS 5 mg when patients experienced an SC; a second 5-mg dose could be given if seizures did not terminate within 10 min or recurred within 10 min-6 h. OUTCOMES: time to RTFBF within 24 h of MDZ-NS administration in SCEs treated with one or two doses, overall (all treated SCEs), and by number of treated SCEs for each patient over the course of the trial (Kaplan-Meier analyses). Time to RTFBF was assessed from the time of MDZ-NS administration in SCEs treated with one dose, and from the time of the second dose in SCEs treated with two doses. RESULTS: One thousand nine hundred ninety-six treated SCEs (one dose: 1,201 [60.2%]; two doses: 795 [39.8%]) in 161 patients were evaluable. In SCEs treated with one or two doses, RTFBF within 24 h of MDZ-NS administration was observed in 97.2% and 94.2% of patients; the estimated median time was 1.2 and 1.3 h and stable from 1 to 45 treated SCEs. The RTFBF profile was generally similar in SCEs treated with one or two doses (30% of patients estimated to have RTFBF within 30 min, almost 50% within 1 h); the proportion of patients with RTFBF between 2 and 6h was slightly higher with one versus two doses. SIGNIFICANCE: In almost all patients, RTFBF was observed within 24 h of MDZ-NS administration. The median time to RTFBF was similar in SCEs treated with one or two doses, and stable over the course of repeated intermittent use. Thus, dose (5 or 10 mg) does not seem to be a key influencer of time for RTFBF after repeated intermittent use.

Schlagwörter

Stichwörter der Autor:innen

Acute repetitive seizureBenzodiazepineEpilepsyRescue medicationSeizure emergency

Autor:innen und Institutionen

  • University of Miami Comprehensive Epilepsy Center, University of Miami Miller School of Medicine, 1150 NW 14th Street #309, Miami, FL 33136, USA. Electronic address: kamil.detyniecki@med.miami.edu.
  • UCB Pharma, Alfred-Nobel-Strasse 10, 40789 Monheim am Rhein, Germany. Electronic address: marcus.brunnert@ucb.com.
  • UCB Pharma, 1950 Lake Park Drive, Smyrna, GA 30080, USA. Electronic address: rita.andrade.campos@gmail.com.
  • UCB Pharma, Allée de la Recherche 60, 1070 Brussels, Belgium. Electronic address: svetlana.dimova@ucb.com.
  • Le Bonheur Comprehensive Epilepsy Program & Neuroscience Institute, Le Bonheur Children's Hospital, 848 Adams Avenue, Memphis, TN 38103, USA; University of Tennessee Health Science Center, 920 Madison Avenue, Memphis, T…

Förderung

  • UCB Pharma

Zitieren

APA

Detyniecki, K., Brunnert, M., Campos, R., Dimova, S., & Wheless, J. W. (2023). Return to full baseline functionality after repeated intermittent use of midazolam nasal spray in patients with seizure clusters: Post hoc analysis of an open-label extension trial. Epilepsy & Behavior, 148, 109483. https://doi.org/10.1016/j.yebeh.2023.109483

Vancouver

Detyniecki K, Brunnert M, Campos R, Dimova S, Wheless JW. Return to full baseline functionality after repeated intermittent use of midazolam nasal spray in patients with seizure clusters: Post hoc analysis of an open-label extension trial. Epilepsy & Behavior. 2023;148:109483. doi:10.1016/j.yebeh.2023.109483

BibTeX
@article{Detyniecki2023,
  author = {Detyniecki, Kamil and Brunnert, Marcus and Campos, Rita and Dimova, Svetlana and Wheless, James W},
  title = {Return to full baseline functionality after repeated intermittent use of midazolam nasal spray in patients with seizure clusters: Post hoc analysis of an open-label extension trial},
  journal = {Epilepsy & Behavior},
  year = {2023},
  volume = {148},
  pages = {109483},
  doi = {10.1016/j.yebeh.2023.109483}
}
Kostenlos starten →